New Findings in Cancer Gene Therapy Described from Hanyang University (Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Research findings on Biotechnology are discussed in a new report. According to news reporting originating from Seoul, South Korea, by NewsRx correspondents, research stated, "Targeted delivery of therapeutic genes to the tumor site is critical for successful and safe cancer gene therapy. The arginine grafted bio-reducible poly (cystamine bisacrylamide-diaminohexane, CBA-DAH) polymer (ABP) conjugated poly (amido amine) (PAMAM), PAM-ABP (PA) was designed previously as an efficient gene delivery carrier."
Our news editors obtained a quote from the research from Hanyang University, "To achieve high efficacy in cancer selective delivery, we developed the tumor targeting bio-reducible polymer, PA-PEG(1k)-RGD, by conjugating cyclic RGDfC (RGD) peptides, which bind alpha(v)beta(3/5) integrins, to the PAM-ABP using polyethylene glycol (PEG, 1 kDa) as a spacer. Physical characterization showed nanocomplex formation with bio-reducible properties between PA-PEG(1k)-RGD and plasmid DNA (pDNA). In transfection assays, PA-PEG(1k)-RGD showed significantly higher transfection efficiency in comparison with PAM-ABP or PA-PEGll,-RAD in alpha(v)beta(3/5) positive MCF7 breast cancer and PANC-1 pancreatic cancer cells. The targeting ability of PA-PEGik-RGD was further established using a competition assay. To confirm the therapeutic effect, the VEGF siRNA expressing plasmid was constructed and then delivered into cancer cells using PA-PEGik-RGD. PA-PEGik-RGD showed 20-59% higher cellular uptake rate into MCF7 and PANC-1 than that of non-targeted polymers. In addition, MCF7 and PANC-1 cancer cells transfected with PA-PEGik-RGD/pshVEGF complexes had significantly decreased VEGF gene expression (51-71%) and cancer cell viability (35-43%) compared with control."
According to the news editors, the research concluded: "These results demonstrate that a tumor targeting bio-reducible polymer with an anti-angiogenic therapeutic gene could be used for efficient and safe cancer gene therapy."
For more information on this research see: Tumor targeting RGD conjugated bio-reducible polymer for VEGF siRNA expressing plasmid delivery. Biomaterials, 2014;35(26):7543-7552. Biomaterials can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; Biomaterials - www.elsevier.com/wps/product/cws_home/30392)
The news editors report that additional information may be obtained by contacting H.A. Kim, Hanyang University, Dept. of Bioengn, Seoul 133791, South Korea. Additional authors for this research include K. Nam and S.W. Kim (see also Biotechnology).
Keywords for this news article include: Asia, VEGF, Biotechnology, Seoul, siRNA, Genetics, Oncology, South Korea, Bioengineering, Protein Kinases, Membrane Proteins, Angiogenic Proteins, Cancer Gene Therapy, Phosphotransferases, Growth Factor Receptors, Small Interference RNAs, Receptor Protein-Tyrosine Kinases, Vascular Endothelial Growth Factors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC